Copyright Reports & Markets. All rights reserved.

Global α4β7 Integrin Antagonists Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global α4β7 Integrin Antagonists Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Natalizumub
    • 1.3.3 Vedolizumab
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global α4β7 Integrin Antagonists Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Inflammatory Bowel Disease (IBD)
    • 1.4.3 Multiple Sclerosis (MS)
    • 1.4.4 Other
  • 1.5 Global α4β7 Integrin Antagonists Market Size & Forecast
    • 1.5.1 Global α4β7 Integrin Antagonists Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global α4β7 Integrin Antagonists Sales Quantity (2021-2032)
    • 1.5.3 Global α4β7 Integrin Antagonists Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Takeda
    • 2.1.1 Takeda Details
    • 2.1.2 Takeda Major Business
    • 2.1.3 Takeda α4β7 Integrin Antagonists Product and Services
    • 2.1.4 Takeda α4β7 Integrin Antagonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Takeda Recent Developments/Updates
  • 2.2 Biogen
    • 2.2.1 Biogen Details
    • 2.2.2 Biogen Major Business
    • 2.2.3 Biogen α4β7 Integrin Antagonists Product and Services
    • 2.2.4 Biogen α4β7 Integrin Antagonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Biogen Recent Developments/Updates
  • 2.3 Sandoz
    • 2.3.1 Sandoz Details
    • 2.3.2 Sandoz Major Business
    • 2.3.3 Sandoz α4β7 Integrin Antagonists Product and Services
    • 2.3.4 Sandoz α4β7 Integrin Antagonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Sandoz Recent Developments/Updates
  • 2.4 Novartis
    • 2.4.1 Novartis Details
    • 2.4.2 Novartis Major Business
    • 2.4.3 Novartis α4β7 Integrin Antagonists Product and Services
    • 2.4.4 Novartis α4β7 Integrin Antagonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Novartis Recent Developments/Updates

3 Competitive Environment: α4β7 Integrin Antagonists by Manufacturer

  • 3.1 Global α4β7 Integrin Antagonists Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global α4β7 Integrin Antagonists Revenue by Manufacturer (2021-2026)
  • 3.3 Global α4β7 Integrin Antagonists Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of α4β7 Integrin Antagonists by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 α4β7 Integrin Antagonists Manufacturer Market Share in 2025
    • 3.4.3 Top 6 α4β7 Integrin Antagonists Manufacturer Market Share in 2025
  • 3.5 α4β7 Integrin Antagonists Market: Overall Company Footprint Analysis
    • 3.5.1 α4β7 Integrin Antagonists Market: Region Footprint
    • 3.5.2 α4β7 Integrin Antagonists Market: Company Product Type Footprint
    • 3.5.3 α4β7 Integrin Antagonists Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global α4β7 Integrin Antagonists Market Size by Region
    • 4.1.1 Global α4β7 Integrin Antagonists Sales Quantity by Region (2021-2032)
    • 4.1.2 Global α4β7 Integrin Antagonists Consumption Value by Region (2021-2032)
    • 4.1.3 Global α4β7 Integrin Antagonists Average Price by Region (2021-2032)
  • 4.2 North America α4β7 Integrin Antagonists Consumption Value (2021-2032)
  • 4.3 Europe α4β7 Integrin Antagonists Consumption Value (2021-2032)
  • 4.4 Asia-Pacific α4β7 Integrin Antagonists Consumption Value (2021-2032)
  • 4.5 South America α4β7 Integrin Antagonists Consumption Value (2021-2032)
  • 4.6 Middle East & Africa α4β7 Integrin Antagonists Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global α4β7 Integrin Antagonists Sales Quantity by Type (2021-2032)
  • 5.2 Global α4β7 Integrin Antagonists Consumption Value by Type (2021-2032)
  • 5.3 Global α4β7 Integrin Antagonists Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global α4β7 Integrin Antagonists Sales Quantity by Application (2021-2032)
  • 6.2 Global α4β7 Integrin Antagonists Consumption Value by Application (2021-2032)
  • 6.3 Global α4β7 Integrin Antagonists Average Price by Application (2021-2032)

7 North America

  • 7.1 North America α4β7 Integrin Antagonists Sales Quantity by Type (2021-2032)
  • 7.2 North America α4β7 Integrin Antagonists Sales Quantity by Application (2021-2032)
  • 7.3 North America α4β7 Integrin Antagonists Market Size by Country
    • 7.3.1 North America α4β7 Integrin Antagonists Sales Quantity by Country (2021-2032)
    • 7.3.2 North America α4β7 Integrin Antagonists Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe α4β7 Integrin Antagonists Sales Quantity by Type (2021-2032)
  • 8.2 Europe α4β7 Integrin Antagonists Sales Quantity by Application (2021-2032)
  • 8.3 Europe α4β7 Integrin Antagonists Market Size by Country
    • 8.3.1 Europe α4β7 Integrin Antagonists Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe α4β7 Integrin Antagonists Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific α4β7 Integrin Antagonists Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific α4β7 Integrin Antagonists Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific α4β7 Integrin Antagonists Market Size by Region
    • 9.3.1 Asia-Pacific α4β7 Integrin Antagonists Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific α4β7 Integrin Antagonists Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America α4β7 Integrin Antagonists Sales Quantity by Type (2021-2032)
  • 10.2 South America α4β7 Integrin Antagonists Sales Quantity by Application (2021-2032)
  • 10.3 South America α4β7 Integrin Antagonists Market Size by Country
    • 10.3.1 South America α4β7 Integrin Antagonists Sales Quantity by Country (2021-2032)
    • 10.3.2 South America α4β7 Integrin Antagonists Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa α4β7 Integrin Antagonists Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa α4β7 Integrin Antagonists Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa α4β7 Integrin Antagonists Market Size by Country
    • 11.3.1 Middle East & Africa α4β7 Integrin Antagonists Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa α4β7 Integrin Antagonists Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 α4β7 Integrin Antagonists Market Drivers
  • 12.2 α4β7 Integrin Antagonists Market Restraints
  • 12.3 α4β7 Integrin Antagonists Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of α4β7 Integrin Antagonists and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of α4β7 Integrin Antagonists
  • 13.3 α4β7 Integrin Antagonists Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 α4β7 Integrin Antagonists Typical Distributors
  • 14.3 α4β7 Integrin Antagonists Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global α4β7 Integrin Antagonists market size was valued at US$ 10350 million in 2025 and is forecast to a readjusted size of US$ 19020 million by 2032 with a CAGR of 9.2% during review period.
    α4β7 integrin antagonists are a class of therapeutic agents that specifically target the α4β7 integrin, a receptor expressed on lymphocytes that plays a crucial role in the homing of these immune cells to the gut. By inhibiting this integrin, these drugs prevent lymphocytes from migrating to inflamed intestinal tissues, making them particularly effective in treating inflammatory bowel diseases such as Crohn's disease and ulcerative colitis.
    This report is a detailed and comprehensive analysis for global α4β7 Integrin Antagonists market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global α4β7 Integrin Antagonists market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global α4β7 Integrin Antagonists market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global α4β7 Integrin Antagonists market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global α4β7 Integrin Antagonists market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for α4β7 Integrin Antagonists
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global α4β7 Integrin Antagonists market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Takeda, Biogen, Sandoz, Novartis, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    α4β7 Integrin Antagonists market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Natalizumub
    Vedolizumab
    Market segment by Application
    Inflammatory Bowel Disease (IBD)
    Multiple Sclerosis (MS)
    Other
    Major players covered
    Takeda
    Biogen
    Sandoz
    Novartis
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe α4β7 Integrin Antagonists product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of α4β7 Integrin Antagonists, with price, sales quantity, revenue, and global market share of α4β7 Integrin Antagonists from 2021 to 2026.
    Chapter 3, the α4β7 Integrin Antagonists competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the α4β7 Integrin Antagonists breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and α4β7 Integrin Antagonists market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of α4β7 Integrin Antagonists.
    Chapter 14 and 15, to describe α4β7 Integrin Antagonists sales channel, distributors, customers, research findings and conclusion.

    Buy now